Starpharma Holdings Limited · ASX:SPL

Starpharma — Investor Presentation (June 2007)

38 slides from Starpharma's investor presentation, June 2007

  1. Slide 1: Starpharma Holdings Limited

    Slide 1: Starpharma Holdings Limited

    Starpharma Holdings Limited ASX:SPL OTCQX:SPHRY June 2007 Dr Jackie Fairley CEO

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set

  3. Slide 3: Company Overview

    Slide 3: Company Overview

    Company Overview ƒ World leader in developing dendrimer products Starpharma Holdings Limited (15/6/07) for pharmaceutical and life-sciences ASX Code SPL Level 1 ADR (OTCQX) SPHRY ƒ Lead product VivaGel™ is being developed (with Share Price SPL AUD 42.5c 12 Month High/Low AUD 64c / 35c >$20M NIH supp

  4. Slide 4: Investment Summary

    Slide 4: Investment Summary

    Investment Summary ƒ Starpharma has a leading topical microbicide (VivaGel™) in development for prevention of sexually transmitted infections (STIs) HIV and genital herpes ƒ Topical microbicides have strong consumer demand and funding support – By age 25 half of all sexually active people in the US

  5. Slide 5: Company Structure

    Slide 5: Company Structure

    Company Structure 8.6% Starpharma Holdings Limited ASX:SPL USOTC:SPHRY 100% 100% Dendritic Nanotechnologies Starpharma Pty Ltd Inc. (DNT) ƒ 36 employees based in Melbourne, ƒ Wholly owned subsidiary based in Australia Michigan, USA (16 employees) ƒ Leading developer of dendrimers as ƒ Leading develo

  6. Slide 6: Shareholding and ADR (SPHRY) Uptake

    Slide 6: Shareholding and ADR (SPHRY) Uptake

    Shareholding and OTCQX:SPHRY ƒ Major shareholders include: ADR (SPHRY) Uptake ƒ The Dow Chemical Company (NASDQ:DOW) OTCQX : SPHRY ƒ Acorn Capital American Depositary Receipts (ADRs) on issue ƒ Biotech Capital 1 ADR = 10 SPL shares 2,000,000 1,800,000 ƒ Queensland Investment Corporation 1,600,000 1,

  7. Slide 7: Technology Overview

    Slide 7: Technology Overview

    Technology Overview Starpharma’s existing Unique Characteristics of Dendrimers: commercial agreements for dendrimers ƒ Precisely defined, synthetic macromolecules (1-10nm) ƒ Precisely defined surface topology Stratus CS® : Cardiac marker ƒ Can be designed to optimize potency, pharmacokinetics and di

  8. Slide 8: Technology Overview (continued)

    Slide 8: Technology Overview (continued)

    Technology Overview (continued) Commercial Advantages of Dendrimers: O O ƒ Key enabling nanoscale technology O O O ƒ Highly versatile technology: O O O Therapeutic Protein O O O O N N – application as drugs (VivaGel), in drug delivery, RNAi N N O N O O O N N delivery, diagnostic & materials applicat

  9. Slide 9: Product Pipeline

    Slide 9: Product Pipeline

    Og starpharma Product Pipeline

  10. Slide 10: Starpharma's Pipeline: Balanced for Risk

    Slide 10: Starpharma's Pipeline: Balanced for Risk

    Starpharma’s Pipeline: Balanced for Risk Pharmaceutical & Medical Products Proof of Concept Lead Clinical Trials Sales VivaGel™ * HSV-2 prevention * HIV prevention * condoms coating & other line extensions ADME Engineering™ * Therapeutic protein PK optimisation Drug Delivery - Small Molecules * Canc

  11. Slide 11: VivaGel - Lead Product for Prevention of STIs

    Slide 11: VivaGel - Lead Product for Prevention of STIs

    VivaGelTM - Lead Product for Prevention of Sexually Transmitted Infections STIs

  12. Slide 12: VivaGel – Lead Product for Prevention of STIs

    Slide 12: VivaGel – Lead Product for Prevention of STIs

    VivaGelTM – Lead Product for Prevention of Sexually Transmitted Infections (STIs) ƒ VivaGel™ is a topical vaginal microbicide being HIV developed to prevent STIs in women ƒ Major health burden in both ƒ Currently being developed under two INDs for the developed and developing countries prevention of

  13. Slide 13: Commercial Opportunity for Microbicides

    Slide 13: Commercial Opportunity for Microbicides

    Commercial Opportunity for Microbicides ƒ Large, addressable markets Estimated Market for ¾ HIV primarily in developing countries microbicides in Developed Countries ¾ HSV-2 in both developing and developed countries Market Average Frequency Penetration of Use Per Annum ƒ Increasing market support f

  14. Slide 14: VivaGel – Product Features and Performance

    Slide 14: VivaGel – Product Features and Performance

    VivaGel™ – Product Features and Performance VivaGel™ Offers „ Market research indicates significant (international) user and payor demand for Several Key microbicide gels Advantages „ VivaGel™ will be “first in class” for Herpes „ Compelling HSV-2 &HIV efficacy and potent contraceptive activity in a

  15. Slide 15: VivaGel - Clinical Trial Status

    Slide 15: VivaGel - Clinical Trial Status

    VivaGel™ - Clinical Trial Status Study No. Site(s) IND Status Participants Application Safety, tolerability and 37 Adelaide, Prevention of Complete pharmacokinetic study of Australia HIV escalating doses of VivaGel in healthy women when administered vaginally, once daily for 7 days Safety and accept

  16. Slide 16: VivaGel - Development stage and plan

    Slide 16: VivaGel - Development stage and plan

    VivaGel™ - Development stage and plan PRODUCT TYPE Therapeutic In vitro In vivo In vivo Market Phase 1 Phase 2 Phase 3 Agent efficacy efficacy safety entry Preventative Expanded Population In vitro In vivo In vivo Market “Drug” Phase 1 Safety Based entry efficacy efficacy safety (VivaGel™) Studies e

  17. Slide 17: VivaGel – Development and Commercial Strategy

    Slide 17: VivaGel – Development and Commercial Strategy

    VivaGelTM – Development and Commercial Strategy ƒ One of the most advanced 2nd generation microbicides for HIV ƒ First in class for HSV-2 ƒ Significant non-dilutive NIH support; strong ongoing support for microbicides ƒ Broad application; chronic-use product VivaGel™ ƒ Partnering/commercial strategi

  18. Slide 18: Portfolio: Overview of Opportunities

    Slide 18: Portfolio: Overview of Opportunities

    Portfolio: Overview of Opportunities Multiple Near-Term Future High-Value Commercial Commercial Opportunities Opportunities Pharmaceutical Industrial Products Life-science Applications Applications siRNA, DNA transfection VivaGel™ Industrial Reagents Chemicals Medical Protein Diagnostics PK Modifica

  19. Slide 19: Portfolio: siRNA Delivery – PrioFect

    Slide 19: Portfolio: siRNA Delivery – PrioFect

    Portfolio: siRNA Delivery – PrioFect™ Concept: Overcome the principle obstacle to the development of RNAi-based drugs … delivery Commercial opportunities for PrioFect™: “RNAi-based therapies have so far failed to take off because of the difficulty of 1. Research reagent market($200 million) getting

  20. Slide 20: Portfolio: siRNA Delivery – PrioFect

    Slide 20: Portfolio: siRNA Delivery – PrioFect

    Portfolio: siRNA Delivery – PrioFect™ Concept: Overcome the principle obstacle to the development of RNAi-based drugs … delivery Technology Inhibiting Protein Expression Significance Potential for Œ Cell specific targeting 100 Œ Enhanced residence time Protein Expression Œ Protection from nucleases

  21. Slide 21: Portfolio: Drug Optimization or Therapeutic Protein PK modification

    Slide 21: Portfolio: Drug Optimization or Therapeutic Protein PK modification

    Portfolio: Drug Optimization or Therapeutic Protein PK (pharmacokinetic) modification Concept: increase half life of drugs by attaching to dendrimer Technology Extending Drug Half Life Significance Potential for Œ less frequent dosing Payload Drug 80 Œ Reduced cost of therapy Circulatory Half-life (

  22. Slide 22: Portfolio: Drug Delivery

    Slide 22: Portfolio: Drug Delivery

    Portfolio: Drug Delivery Concept: Attach drugs to dendrimers to control and modify distribution Technology Dendrimers can be Targeted Significance Optional Potential for Targeting Payload Œ Improved efficacy of drugs Element Drug Œ Reduced off-target effects Œ Product lifecycle management Œ Improved

  23. Slide 23: Portfolio: Other Early Commercial Opportunities

    Slide 23: Portfolio: Other Early Commercial Opportunities

    Portfolio: Other Early Commercial Opportunities* Sector Discussions with… Application Research Reagents Major Reagent manufacturers Enhanced fluorescent dye performance Major Reagent manufacturers Other Laboratory reagents Oil "Top 5" US Oil Company Lubricant additives Plastics Large Automotive Comp

  24. Slide 24: Partnerships and Collaborators

    Slide 24: Partnerships and Collaborators

    Partnerships and Collaborators Industry Collaborators Research/ University Collaborators NICHD NIAID 24

  25. Slide 25: Key Management

    Slide 25: Key Management

    Key Management ƒ Over 15 years international business development and general management Dr Jackie Fairley, CEO experience in pharmaceuticals and biotechnology ƒ Former senior roles with CSL and Faulding (Mayne Pharma) Dr Paul Barrett, VP Business ƒ Significant experience in marketing and business d

  26. Slide 26: Key Investment Highlights

    Slide 26: Key Investment Highlights

    Key Investment Highlights ƒ Compelling competitive advantages VivaGel™: A Unique ƒ Clinical candidate with Significant support from NIH (>US$20M) Lead Product ƒ First in class for genital herpes ƒ HIV and genital herpes at epidemic proportions Significant Commercial (Genital herpes: US 22% adults &

  27. Slide 27: Starpharma Holdings Limited

    Slide 27: Starpharma Holdings Limited

    Starpharma Holdings Limited ASX:SPL OTCQX:SPHRY Dr Jackie Fairley, CEO +613 85322704 SPL US$M Market Capitalisation ~60 Further information: NIH Support >26 www.starpharma.com Cash on Hand (Mar 07) 10.7 info@starpharma.com

  28. Slide 28: Supplementary Information

    Slide 28: Supplementary Information

    Og starpharma Upplementary | ntormation

  29. Slide 29: Starpharma: 06/07 Highlights

    Slide 29: Starpharma: 06/07 Highlights

    Starpharma: 06/07 Highlights Acquisition of DNT SPL acquires US company DNT Dow becomes SPL’s largest holder Integration of SPL and DNT complete Richard Hazelton appointment Retired Dow Corning Chairman/CEO appointed to SPL Board VivaGel™ clinical trial progress Expanded safety trial in men complete

  30. Slide 30: Portfolio: Fluorescent Reagents

    Slide 30: Portfolio: Fluorescent Reagents

    Portfolio: Fluorescent Reagents Concept: Attach fluorescent dyes on dendrimers to enhance biomolecular signal Technology Enhanced, Stabilized Signal Significance >4X Longer Lasting! Potential for Œ Fluorescence Microscopy Linker Dye Œ Microarrays Œ Antibody based kits (ELISA) 10X Œ In vitro Diagnost

  31. Slide 31: Portfolio: Cosmetic Ingredient Solubilizer

    Slide 31: Portfolio: Cosmetic Ingredient Solubilizer

    Portfolio: Cosmetic Ingredient Solubilizer Concept: Use dendrimers to enhance solubility, stability, processing Technology Low % = Improve Solubility Significance Poorly Potential for Soluble Œ Increasing ingredient loading Ingredient Œ Stabilize ingredient Œ Improved processing Œ Allowing new ingre

  32. Slide 32: VivaGel: Animal Efficacy results – SHIV/HIV Protection

    Slide 32: VivaGel: Animal Efficacy results – SHIV/HIV Protection

    VivaGel™: Animal Efficacy results SHIV/HIV Protection Advantage: VivaGel™ is NOT a surfactant Surfactants damage epithelial cells INCREASING the chance of HIV transmission. VivaGel is NOT a surfactant and has been found not to damage epithelial cells in human trials. This is not true of all microbic

  33. Slide 33: VivaGel: Animal Efficacy results (continued) – HSV Protection

    Slide 33: VivaGel: Animal Efficacy results (continued) – HSV Protection

    VivaGel™: Animal Efficacy results (continued) HSV Protection VivaGel™: animals protected from HSV-2 100% Approximately 45 million Americans (26% 90% Approximately 45 million Americans (26% ofofwomen women and 18%ofofmen) and 18% men)are areinfected infected 80% with HSV-2, the causative agent of gen

  34. Slide 34: VivaGel: Potent Contraceptive Activity in Rabbits

    Slide 34: VivaGel: Potent Contraceptive Activity in Rabbits

    VivaGel™ : Potent Contraceptive Activity in Rabbits ƒ Recent study has shown that SPL7013, the active ingredient in its VivaGel™, exhibits a potent contraceptive effect in rabbits ƒ Independent study undertaken at Johns Hopkins University under an NIH grant ƒ Fertility was reduced by more than 75% b

  35. Slide 35: VivaGel: Significant Advantages Over Competitors

    Slide 35: VivaGel: Significant Advantages Over Competitors

    VivaGel™ : Significant Advantages Over Competitors Competitor Category Key Disadvantages VivaGel™ Advantages HSV-2 VivaGel™ is the only microbicide being developed to prevent genital herpes Surfacants/Detergents „ Ulceration possible „ No surfactant properties „ Potential increased risk of „ Non-irr

  36. Slide 36: Pipeline: Commercialisation Strategy

    Slide 36: Pipeline: Commercialisation Strategy

    Pipeline: Commercialisation Strategy Product/ Projected / actual Category Approach Stage Application Income type Milestones VivaGel™ Late stage partnering deal to retain value Clinical Royalties “In house” Milestones Other Drugs, Pharmaceutical Preclinical out-license Pre-clincial e.g cancer therape

  37. Slide 37: Pipeline: Drug Delivery & PK Modification of Protein Therapeutics

    Slide 37: Pipeline: Drug Delivery & PK Modification of Protein Therapeutics

    Pipeline: Drug Delivery & PK Modification of Protein Therapeutics Starpharma’s dendrimers can be designed to optimize the Pharmacokinetics (PK) of: Small molecule drugs O O Therapeutic proteins O O O Peptides O O O Therapeutic Protein O O Plasma residence time increases with dendrimer size, but: O O

  38. Slide 38: RNAi therapeutics

    Slide 38: RNAi therapeutics

    RNAi therapeutics Company Clinical Development Pre-clinical development Acuity Ph II AMD & DME anti-inflammatories & anti-infectives Alnylam Ph 1 2006 (RSV) pandemic flu, spinal cord injury, Parkinson’s, cystic fibrosis, hypercholesterolemia, neuropathic pain Sirna Ph II AMD (w/ Allergan) Asthma, RS

Source: Internet Archive copy of starpharma.com

More decks from Starpharma Holdings Limited

All 67 Starpharma decks